MyCEI Login


ART Highlights from CROI 2024


Published Date: 04/22/2024

Expiration Date: 03/18/2027

CE Credit: CME:1


Every year, the Conference on Retrovirology and Opportunistic Infections (CROI) leads the way in the science and clinical trials of HIV treatment and prevention. Once again, PRN is proud to have Trip Gulick spotlight the most important developments in ART from CROI 2024.


Roy M. Gulick,MD, MPH

Roy M. Gulick, MD, MPH research interests include designing, conducting and analyzing clinical trials to refine antiretroviral therapy strategies for HIV treatment and prevention and assess agents with new mechanisms of action. He currently serves as Principal Investigator of the Cornell-New Jersey HIV Clinical Trials Unit of the ACTG and the HIV Prevention Trials Network (HPTN), sponsored by the NIH.

Learning Objectives

  • Learn about new data from CROI on antiretroviral therapy efficacy.
  • Learn about new data from CROI on antiretroviral therapy toxicities.
  • Learn about new data from CROI on investigational antiretroviral drugs.

Continuing Education Credit Information